Washington, D.C., May 8, 2017—On Friday, the National Health Council (NHC) and the National Organization for Rare Disorders (NORD), submitted a letter from more than 120 patient advocacy organizations to members of Congress urging them to swiftly reauthorize the FDA user fees.
The letter, in part, reads, “The chronic and rare disease and disability patient communities rely on FDA to ensure that innovative, safe, and effective treatments reach those in need. We thank Congress for moving forward with these critical funding mechanisms, and look forward to their swift and unimpeded passage.”
The current user fee agreements, which are scheduled to be marked up this Wednesday in the Senate HELP Committee, are the culmination of months of negotiation between FDA and the medical product industry, with significant input from the patient advocacy community.
Patient advocates, representing the millions of men, women, and children in the United States living with chronic or rare diseases and disabilities, stand behind these agreements and ask that they are reauthorized as quickly as possible.
Read the full letter here.
